Arcutis Biotherapeutics (ARQT) announced the FDA’s acceptance of a supplemental New Drug Application, sNDA, forZORYVE cream 0.05%, a once-daily, next generation phosphodiesterase-4 inhibitor, for the topical treatment of mild to moderate AD in children 2 to 5 years old. The FDA has set a PDUFA target action date of October 13, 2025 for this application.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics: Strong Buy Rating Backed by Surpassing Sales and Promising Pipeline
- Strong Sales Growth and Financial Stability Drive Buy Rating for Arcutis Biotherapeutics
- Arcutis Biotherapeutics Reports Strong 2024 Revenue Growth
- Strong Market Position and Growth Potential for Arcutis Biotherapeutics Driven by Zoryve’s Success and Strategic Initiatives
- Closing Bell Movers: Intuit up 6%, Workday up 11% on earnings